Table 2.
Non-insulin antihyperglycemic medication profile before and after insulin initiation.
| Antihyperglycemic treatment | Treatment before initiating insulin (n=931) | Treatment after initiating any insulin (n=931) | Treatment after initiating long acting insulin only (n=530) | Treatment after initiating other insulin typesb (n=401) |
|---|---|---|---|---|
| No antihyperglycemicsa | 27 (2.9) | 115 (12.4) | 30 (5.7) | 85 (21.2) |
| Single compounda | 150 (16.1) | 276 (29.6) | 130 (24.5) | 146 (36.4) |
| Metformin | 78 (8.4) | 159 (17.1) | 62 (11.7) | 97 (24.2) |
| Sulfonylurea | 58 (6.2) | 82 (8.8) | 47 (8.9) | 35 (8.7) |
| Thiazolidinedione | 7 (0.8) | 18 (1.9) | 11 (2.1) | 7 (1.7) |
| Meglitinide | 3 (0.3) | 7 (0.8) | 6 (1.1) | 1 (0.2) |
| DPP-4 inhibitor | 2 (0.2) | 4 (0.4) | 2 (0.4) | 2 (0.5) |
| GLP-1 receptor agonist | 2 (0.2) | 4 (0.4) | 1 (0.2) | 3 (0.7) |
| α-glucosidase inhibitor | 0 | 2 (0.2) | 1 (0.2) | 1 (0.2) |
| Two compoundsa | 433 (46.5) | 378 (40.6) | 251 (47.4) | 127 (31.7) |
| Metformin + Sulfonylurea | 284 (30.5) | 228 (24.5) | 145 (27.4) | 83 (20.7) |
| Metformin + TZD | 38 (4.1) | 45 (4.8) | 29 (5.5) | 16 (4.0) |
| Metformin + DPP-4 inhibitor | 16 (1.7) | 23 (2.5) | 15 (2.8) | 8 (2.0) |
| Metformin + GLP-1 receptor agonist | 14 (1.5) | 19 (2.0) | 14 (2.6) | 5 (1.2) |
| Sulfonylurea + TZD | 42 (4.5) | 22 (2.4) | 15 (2.8) | 7 (1.7) |
| Other two-compound combinations | 39 (4.2) | 41 (4.4) | 33 (6.2) | 8 (2.0) |
| Three or more compoundsa | 321 (34.5) | 162 (17.4) | 119 (22.5) | 43 (10.7) |
| Metformin + Sulfonylurea + TZD | 165 (17.7) | 74 (7.9) | 54 (10.2) | 20 (5.0) |
| Metformin + Sulfonylurea + DPP-4 inhibitor | 35 (3.8) | 24 (2.6) | 21 (4.0) | 3 (0.7) |
| Metformin + Sulfonylurea + GLP-1 receptor agonist | 37 (4.0) | 22 (2.4) | 14 (2.6) | 8 (2.0) |
| Other combinations | 84 (9.0) | 42 (4.5) | 30 (5.7) | 12 (3.0) |
Values are frequency (% of column). TZD, thiazolidinedione.
a
Rows indicating the number of antihyperglycemic compounds are mutually exclusive.
b
Includes participants using rapid acting, short acting, or premixed insulin, with or without long acting insulin.